Home / Business and Economy / Incyte Nears $2B Deal for Star Therapeutics
Incyte Nears $2B Deal for Star Therapeutics
7 Jun
Summary
- Incyte Pharma is close to acquiring Star Therapeutics.
- The deal could reach up to $2 billion in value.
- Upfront payment is $1.25 billion in cash.
Incyte Pharma is reportedly close to finalizing a substantial acquisition of Star Therapeutics, a developer of drugs for blood disorders. The deal, which could be worth as much as $2 billion, represents a significant move for Incyte in the competitive biotechnology sector.
The proposed transaction involves an upfront cash payment of $1.25 billion to Star's existing venture capital investors. Furthermore, an additional $750 million is earmarked, pending the achievement of specific performance benchmarks set for Star Therapeutics' pipeline and products.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
